Literature DB >> 32203916

Production and validation of human induced pluripotent stem cell line from sporadic amyotrophic lateral sclerosis (SALS).

Jun Ma1, Baofeng Feng2, Desheng Kong2, Jingjing He2, Ruiyun Guo2, Asiamah Ernest Amponsah2, Wei Zhang2, Shuhan Zhang2, Fei Lv2, Yongzhou Song3, Aijing Liu3, Huixian Cui4.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with the loss of upper motor neurons in the cortex and lower motor neurons in the brain stem and spinal cord regressively. The vast majority of ALS cases have no familial history are apparently sporadic (SALS), making the modeling of SALS essential to the development of ALS therapeutics. Therefore, human induced pluripotent stem cell (iPSC) from peripheral blood mononuclear cells of a 64-year-old SALS patient were produced using a virus-free protocol and characterized using standard validate methods. This generated iPSC line could be useful to reveal SALS mechanisms and screen drug development.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  differentiation; induced pluripotent stem cell; reprogramming; sporadic amyotrophic lateral sclerosis

Mesh:

Year:  2020        PMID: 32203916     DOI: 10.1016/j.scr.2020.101760

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  2 in total

Review 1.  Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention.

Authors:  Teresa Cunha-Oliveira; Liliana Montezinho; Catarina Mendes; Omidreza Firuzi; Luciano Saso; Paulo J Oliveira; Filomena S G Silva
Journal:  Oxid Med Cell Longev       Date:  2020-11-15       Impact factor: 6.543

2.  Autophagy-Mediated Inflammatory Cytokine Secretion in Sporadic ALS Patient iPSC-Derived Astrocytes.

Authors:  Asiamah Ernest Amponsah; Ruiyun Guo; Xin Liu; Jinyu Zhang; Xiaofeng Du; Zijing Zhou; Jingjing He; Jun Ma; Huixian Cui
Journal:  Oxid Med Cell Longev       Date:  2022-08-22       Impact factor: 7.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.